SINGAPORE–(BUSINESS WIRE)–#ClinicalTrials–Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the SINGAPORE–(BUSINESS WIRE)–#ClinicalTrials–Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the

Novotech Appoints Anand Tharmaratnam as New CEO

SINGAPORE–(BUSINESS WIRE)–#ClinicalTrials–Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer.

Dr. Tharmaratnam brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will be based at the company’s new global headquarters in Singapore.

The appointment follows a thoughtful and considered process. In early September 2025, Novotech’s former CEO Dr. John Moller informed employees of his intention to step down from the position at the end of last year, after nine years in the CEO role. The decision followed the successful completion of the company’s capital raising in March 2025, which brought in GIC and Temasek as new investors alongside long-term supporter and leading global asset management firm, TPG.

A critical care physician by training, Dr. Tharmaratnam previously spent 23 years at the global CRO Quintiles and its successor organization IQVIA, including 10 years on the global executive committees of the respective companies as Head of Asia and Japan, a role he held until 2020. As Chairman of Novotech over the past four years, Dr. Tharmaratnam has been instrumental in providing leadership and guidance to support Novotech’s growth into new markets, as well as the expansion of the company’s innovative service capabilities in clinical research. With his vision and experience, together with the support of Novotech’s long-standing investor TPG, alongside GIC and Temasek, the company is well positioned to continue to grow as a global, biotech-focused full-service clinical CRO.

Dr. Tharmaratnam said: “On behalf of the Board, I would like to take this opportunity to extend our heartfelt thanks to John for his leadership and commitment to Novotech over the past nine years, and through a remarkable period of growth. John and I have already been working closely together over the past months to ensure a seamless transition, and we also look forward to welcoming John back to Novotech in a board role later in 2026.”

Looking ahead, Dr. Tharmaratnam added: “It has been a privilege to be part of Novotech’s tremendous growth over the past four years as Chairman. As the company enters its next phase of growth, our reputation as the leading biotech CRO in Asia-Pacific will remain a clear differentiator. The company will expand its global footprint, strengthen its scientific capabilities, and leverage technology & data to support increasingly global and complex biotech programs. Novotech will continue to deliver impactful and innovative outcomes for clients to help advance future medicines.”

About Novotech

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.

For more information on Novotech visit www.Novotech-CRO.com

Contacts

For media inquiries:

Novotech
Toyna Chin

(USA) +1 415 364 8135

mediacontact@novotech-cro.com

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.10038
$0.10038$0.10038
-0.72%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

FBI says North Korea’s Kimsuky APT uses malicious QR codes to spearphish U.S. entities

FBI says North Korea’s Kimsuky APT uses malicious QR codes to spearphish U.S. entities

The post FBI says North Korea’s Kimsuky APT uses malicious QR codes to spearphish U.S. entities appeared on BitcoinEthereumNews.com. The FBI says Kimsuky APT, a
Share
BitcoinEthereumNews2026/01/10 02:55
a16z targets AI and crypto after $15B fundraising year in 2025

a16z targets AI and crypto after $15B fundraising year in 2025

The post a16z targets AI and crypto after $15B fundraising year in 2025 appeared on BitcoinEthereumNews.com. Andreessen Horowitz (a16z) secured over $15 billion
Share
BitcoinEthereumNews2026/01/10 03:13
Stablecoin Market: Urgent Warning of a Zero-Sum Future

Stablecoin Market: Urgent Warning of a Zero-Sum Future

BitcoinWorld Stablecoin Market: Urgent Warning of a Zero-Sum Future A significant warning has emerged from financial giant JPMorgan, signaling a potentially challenging future for the stablecoin market. This isn’t just a minor blip; it’s a stark reminder that the booming world of digital assets faces a critical juncture, especially for those relying on the stability of stablecoins. JPMorgan’s recent research note suggests that unless the broader cryptocurrency market expands dramatically, stablecoin issuers are heading towards a fierce ‘zero-sum game’ scenario. The Alarming Truth About the Stablecoin Market What exactly does a ‘zero-sum game’ mean for the stablecoin market? Essentially, it implies that for one stablecoin to gain market share, another must lose it. This isn’t about overall growth where everyone benefits; it’s about a fixed pie where new entrants only succeed by taking a slice from existing players. JPMorgan analysts point to a rapidly increasing number of new stablecoin projects vying for attention. Tether recently announced its unregulated stablecoin, USAT. Hyperliquid plans to launch USDH, aiming to reduce its dependence on Circle’s USDC. Even traditional fintech powerhouses like Robinhood and Revolut are developing their own stablecoins. This surge of new issuers intensifies competition significantly. While the overall stablecoin market capitalization has reached an impressive $278 billion, its share of the total crypto market has remained stagnant, averaging below 8% since 2020. This stagnation, according to JPMorgan, is a key indicator of the brewing zero-sum challenge. Why is the Stablecoin Market Becoming So Crowded? The influx of new players into the stablecoin market isn’t accidental; it’s driven by various strategic motivations. Many projects aim to gain greater control over their financial infrastructure and reduce reliance on third-party stablecoins. For instance, Hyperliquid’s move to USDH is a clear example of a platform seeking self-sufficiency and potentially lower operational costs. Furthermore, established fintech firms like Robinhood and Revolut see stablecoins as a natural extension of their existing services. They can integrate these digital assets into their platforms, offering new functionalities and potentially attracting a broader user base. However, this expansion comes with a caveat: if the overall crypto market doesn’t grow proportionally, these new offerings will merely fragment the existing demand, making profitability and widespread adoption harder to achieve for all. The core challenge remains the limited expansion of the total crypto market relative to the growing supply of stablecoins. This dynamic creates an environment where innovation must go hand-in-hand with genuine market expansion, not just internal competition. Navigating the Competitive Stablecoin Market Landscape So, what does this intense competition mean for users and the broader crypto ecosystem? For one, it could lead to increased innovation as issuers strive to differentiate their offerings through better features, lower fees, or enhanced security. However, it also presents potential risks, particularly if some stablecoins fail to gain traction or face liquidity issues in a highly competitive environment. Users should exercise caution and conduct thorough due diligence when choosing stablecoins. For existing giants like USDC, the entry of new competitors means they must continue to innovate and maintain their market leadership. Regulatory clarity also plays a crucial role here. As more entities enter the space, the demand for clear, consistent regulations will only grow, potentially shaping the future landscape of the stablecoin market significantly. Ultimately, the long-term health of the stablecoin ecosystem hinges on the ability of the entire cryptocurrency market to attract new capital and users. Without this broader expansion, JPMorgan’s warning of a zero-sum game could become a stark reality. In conclusion, JPMorgan’s recent warning serves as a potent reminder of the escalating competition within the stablecoin market. While innovation and new entrants are exciting, the core challenge lies in the stagnant growth of the broader crypto market. For stablecoins to truly thrive beyond a zero-sum dynamic, a significant influx of new capital and users into the entire cryptocurrency ecosystem is paramount. The future success of these digital anchors depends on collective market expansion, not just internal rivalry. Frequently Asked Questions About the Stablecoin Market Q1: What is a ‘zero-sum game’ in the context of the stablecoin market? A1: A ‘zero-sum game’ means that for one stablecoin to gain market share, another stablecoin must lose an equivalent amount. It implies that the overall market size for stablecoins is not growing, forcing issuers to compete for a fixed pool of users and capital. Q2: Why is JPMorgan concerned about the stablecoin market? A2: JPMorgan is concerned because despite the stablecoin market’s growth in total value, its share of the overall crypto market capitalization has stagnated. With many new entrants, they believe competition will intensify, leading to a zero-sum dynamic unless the broader crypto market significantly expands. Q3: Which new stablecoin issuers are mentioned in the warning? A3: The warning highlights new entrants such as Tether’s unregulated stablecoin USAT, Hyperliquid’s planned USDH, and stablecoins being developed by fintech firms Robinhood and Revolut. Q4: What could be the implications for users of stablecoins? A4: For users, increased competition could lead to more innovative features, potentially lower fees, and better services. However, it also means a greater need for due diligence to assess the stability and reliability of various stablecoins, especially if some struggle in a crowded market. Q5: How can the stablecoin market avoid a zero-sum outcome? A5: According to JPMorgan, avoiding a zero-sum outcome requires significant expansion of the broader cryptocurrency market. This means attracting new capital and users into the entire crypto ecosystem, thereby growing the ‘pie’ rather than just re-dividing existing slices. Did JPMorgan’s warning about the stablecoin market catch your attention? Share this crucial insight with your network and join the conversation about the future of digital assets. Your thoughts and perspectives are invaluable! To learn more about the latest stablecoin market trends, explore our article on key developments shaping stablecoin market institutional adoption. This post Stablecoin Market: Urgent Warning of a Zero-Sum Future first appeared on BitcoinWorld.
Share
Coinstats2025/09/19 15:45